Statin Therapy as a Protective Technique for Potential Cardiovascular Event Occurrences Among Breast Cancer Patients Undergoing Chemotherapy Treatment
I. Evaluate the feasibility of administering Rosuvastatin to breast cancer patients
undergoing treatment with anthracyclines, paclitaxel, cyclophosphamide, and trastuzumab for
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
Arm I: Patients receive rosuvastatin orally (PO) once daily for 3 months in the absence of
disease progression or unacceptable toxicity.
Arm II: Patients receive placebo PO once daily for 3 months in the absence of disease
progression or unacceptable toxicity.
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment
Whether the rate of statin adherence for patients taking chemotherapy is comparable to the rate of adherence found in prior studies (i.e., JUPITER study)
Comprehensive Cancer Center of Wake Forest University
United States: Institutional Review Board
|Wake Forest University Health Sciences||Winston-Salem, North Carolina 27157|